Back to Newsroom

Pharnext Announces Support of the First Patient-Centered Charcot-MarieTooth Summit Organized by the Hereditary Neuropathy Foundation

Paris, Oct. 4, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced its support of the first annual Patient-Centered Charcot-Marie-Tooth (CMT) Summit organized by the Hereditary Neuropathy Foundation (HNF) on Thursday Oct. 6, 2016 in New York City.

Click here to read the full release